Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.60 |
| ▸ | ITGAV | P06756 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24336633 | 0.89 | ITGB3 (0.69) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL21705487 | 0.87 | ITGB3 (0.66) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7321895 | 0.80 | ITGB3 (0.74) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL21705482 | 0.80 | ITGB3 (0.72) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL14427044 | 0.80 | ITGB3 (0.72) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7313762 | 0.78 | ITGB3 (0.71) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7444460 | 0.77 | ITGB3 (0.72) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7320414 | 0.77 | ITGB3 (0.71) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7310911 | 0.76 | ITGB3 (0.71) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL17118297 | 0.75 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643393-B2 | Integrin antagonists | ITGA2B, ITGA2, ITGB2 | ITGB3 9/4885ITGA2B 1/4885ITGAV 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.